OrbiMed Advisors PASG Position
ExitedOrbiMed Advisors exited their position in Passage BIO, Inc. (PASG) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds PASG.
About Passage BIO, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Full company profile →Short Interest
4.1%
2.7 days to cover
OrbiMed Advisors PASG Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -59,046 | $0 |
| Q3 2025 | Decreased | 59,046 | -5,996,254 | $474K |
| Q2 2025 | Decreased | 6,055,300 | -979,326 | $2.4M |
| Q1 2025 | Decreased | 7,034,626 | -370,243 | $2.5M |
| Q4 2024 | Decreased | 7,404,869 | -2,418,007 | $4.2M |
| Q3 2024 | Decreased | 9,822,876 | -301,700 | $6.9M |
| Q2 2024 | Held | 10,124,576 | — | $8.0M |
| Q1 2024 | Held | 10,124,576 | — | $13.7M |
| Q4 2023 | Held | 10,124,576 | — | $10.2M |
| Q3 2023 | Held | 10,124,576 | — | $6.7M |
| Q2 2023 | Increased | 10,124,576 | +1,192,577 | $9.5M |
| Q1 2023 | New | 8,931,999 | +8,931,999 | $8.6M |
Frequently Asked Questions
Does OrbiMed Advisors own PASG?
No. OrbiMed Advisors exited their position in Passage BIO, Inc. (PASG) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own PASG?
1 specialist biotech hedge fund currently holds PASG, including Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy PASG?
OrbiMed Advisors's position in PASG was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's PASG position increasing or decreasing?
OrbiMed Advisors completely exited their PASG position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PASGCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →